| Project/Area Number |
06304037
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 総合 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | NARA MEDICAL UNIVERSITY |
|---|
Principal Investigator |
OKAJIMA Eigoro NARA MEDICAL UNIV.PROFESSOR, 医学部, 教授 (50075115)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SHIRAI Tomoyuki NAGOYA CITY UNIV., MEDICALSCHOOL,PROFESSOR, 医学部, 教授 (60080066)
YOSHIDA Osamu KYOTO UNIV., FACULTY OF MEDICINE,PROFESSOR, 医学部, 教授 (70025584)
OKADA Kioki NIPPON UNIV., MEDICAL SOOL,PROFESSOR, 医学部, 教授 (70059301)
ORIKASA Seiichi TOHOKU UNIV., MEDICAL SCHOOL,PROFESSOR, 医学部, 教授 (60001004)
TSUKAMOTO Taiji HOKKAIDO UNIV., MEDICAL SCHOOL,PROFESSOR, 医学部, 教授 (50112454)
|
|---|
| Project Period (FY) |
1994 – 1996
|
| Keywords | benign prostate hyperplasis / ethiology / criteria for diagnosis and severity / criteria for treatment efficacy |
|---|
| Research Abstract |
The objectives of this research are to establish the standard criteria for severity and treatment efficacy in Benign Prostate hyperplasia (BPH) which will contribute to harmonize the optimum treatment indication, and to evaluate the treatment efficacy to the various modalities of treatment standing on the same levels. For this purpose, the research group was organized including the outstanding researchers from pathologist to urology. To establish the standard criteria, clinical data of BPH patients were accumulated from 10 institutions as a collaborate study. The date were constituted of symptom (internatoinal prostate symptom score ; I-PSS), QOL (QOL scorein I-PSS), function (Maximum flow rate ; Qmax and residual urine ; RU) and anatomy (prostate volume ; PV) as well as the evaluations in sererity and efficacy evaluations into 5 grades by attending doctors of each institution. The severity criteria of each domain is classified into 3 grades, mild, moderate and severe depending upon these data. The general severity is also classified into 3 grades depending on the number of the grade in each domain evaluated. The criteria of treatment efficacy was classified into 4 categories, excellent, good fair, poor/worse depending on the difference between pre-and post- treatment in each domain. The PV was excluded form the criteria of treatment efficacy because some treatment modalities are subjecting the volume reduction of the prostate.
The clinical usefulness of this standard criteria for severity and treatment efficacy in BPH will be evaluated through prospective study, and revised in future to adapt in practical use and clinical trials on BPH.
|
